Novo Nordisk and Aarhus University team up on world-class talents

Novo NordiskNovo Nordisk and Aarhus University's Science and Technology faculty today signed a collaboration agreement to strengthen protein technology research and development. Under the new collaboration, a total of nine PhD students will be offered three-year research scholarships. The research will take place in the leading technological research environments at Science and Technology, Aarhus University, and in Novo Nordisk's research and development department in Måløv. The Aarhus Novo Nordisk Science and Talent Network programme will run for five years.

"This is the starting point for a stronger collaboration between Aarhus University and Novo Nordisk, which is exploiting the powerful and growing synergy between research and industrial development," says Niels Chr. Nielsen, dean of the Faculty of Science and Technology, Aarhus University. "The collaboration creates a unique opportunity to focus on talent development while uniting and further developing excellent research environments within the development of protein- and peptide-based medicines at Aarhus University and Novo Nordisk."

Aarhus University and Novo Nordisk are also seizing the opportunity to initiate collaboration on education. The intention is that students will have the opportunity to combine highly theoretical training directly with practical and industry-relevant problems.

"With this agreement, we are building an important relationship with some of the best research environments at Aarhus University in areas of technology that are significant to Novo Nordisk. Partnerships like this with leading research environments - and the training of talented young researchers - are important for driving innovation at Novo Nordisk," says Peter Kurtzhals, senior vice president, Global Research, Novo Nordisk.

Aarhus University belongs to the scientific elite and has, among other things, core competences within organic chemistry, protein chemistry and structural biology. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. Over 5,400 employees work in research and development at Novo Nordisk in Denmark, the US and China, many of them in partnership with external biotech and academic researchers. The company has about 120 PhD students and postdocs worldwide - and soon also some in Aarhus.

A joint steering committee with members from Aarhus University and Novo Nordisk will have overall responsibility for the programme. The first three PhD students are expected to begin their research in 2017.

About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 75 countries and markets its products in more than 180 countries.

Most Popular Now

Novartis announces plan to initiate clinical trial…

Novartis today announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the effic...

Gilead announces results from Phase 3 trial of inv…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigation...

AstraZeneca and Oxford University announce landmar…

AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine a...

Sanofi and Regeneron provide update on U.S. Phase …

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzar...

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...

Loss of smell associated with milder clinical cour…

Following an earlier study that validated the loss of smell and taste as indicators of SARS-CoV-2 infection, researchers at UC San Diego Health report in newly published ...

Can an existing HIV medication slow the spread of …

A team of scientists from St. Michael's Hospital, Sinai Health and Sunnybrook Health Sciences Centre have launched a clinical trial to understand whether an existing drug...